Bionano Genomics, Inc.
BNGONASDAQHealthcare● Active
$1.18
+$0.01(+0.85%)
Market Cap$3874425
P/E Ratio—
52W High$5.5
52W Low$1.06
Bionano Genomics, Inc. (BNGO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BNGO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.76
Est. -$0.81 · +6.2%
Revenue
$0.01B
Est. $0.01B · +1.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
BNGO reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.70 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.81 | -$0.76 | +6.2% | $0.01B | $0.01B | +1.8% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$0.81 | -$0.03 | +96.3% | $0.01B | $0.01B | +0.9% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$1.81 | -$1.59 | +12.2% | $0.01B | $0.01B | -6.8% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$2.69 | -$1.99 | +26.0% | $0.01B | $0.01B | -6.8% |
| ▲ Q2 FY2025 | May 14, 2025 | -$3.49 | -$1.15 | +67.0% | $0.01B | $0.01B | +3.3% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$6.00 | -$57.49 | -858.2% | $0.01B | $0.01B | +31.7% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.21 | -$19.16 | -9023.8% | $0.01B | $0.01B | -3.6% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.76
EPS Est.
-$0.81
EPS Surpr.
+6.2%
Revenue
$0.01B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.03
EPS Est.
-$0.81
EPS Surpr.
+96.3%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$1.59
EPS Est.
-$1.81
EPS Surpr.
+12.2%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$1.99
EPS Est.
-$2.69
EPS Surpr.
+26.0%
Revenue
$0.01B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$1.15
EPS Est.
-$3.49
EPS Surpr.
+67.0%
Revenue
$0.01B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$57.49
EPS Est.
-$6.00
EPS Surpr.
-858.2%
Revenue
$0.01B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$19.16
EPS Est.
-$0.21
EPS Surpr.
-9023.8%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +6.2% | $1.26 | $1.25 | -0.79% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +96.3% | $1.15 | $1.46 | +26.96% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +12.2% | $1.60 | $1.47 | -8.13% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +26.0% | $3.24 | $3.21 | -0.93% |
| ▲ Q2 FY2025 | May 14, 2025 | +67.0% | $3.95 | $3.74 | -5.32% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -858.2% | $2.90 | $2.79 | -3.79% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -9023.8% | $16.61 | $15.35 | -7.59% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -3321.4% | $30.79 | $25.90 | -15.88% |
Q2 FY2026-0.79%
Report Date
May 13, 2026
EPS Beat/Miss
+6.2%
Price Before
$1.26
Price After
$1.25
Q1 FY2026+26.96%
Report Date
Mar 23, 2026
EPS Beat/Miss
+96.3%
Price Before
$1.15
Price After
$1.46
Q4 FY2025-8.13%
Report Date
Nov 13, 2025
EPS Beat/Miss
+12.2%
Price Before
$1.60
Price After
$1.47
Q3 FY2025-0.93%
Report Date
Aug 14, 2025
EPS Beat/Miss
+26.0%
Price Before
$3.24
Price After
$3.21
Q2 FY2025-5.32%
Report Date
May 14, 2025
EPS Beat/Miss
+67.0%
Price Before
$3.95
Price After
$3.74
Q1 FY2025-3.79%
Report Date
Mar 31, 2025
EPS Beat/Miss
-858.2%
Price Before
$2.90
Price After
$2.79
Q4 FY2024-7.59%
Report Date
Nov 14, 2024
EPS Beat/Miss
-9023.8%
Price Before
$16.61
Price After
$15.35
Q3 FY2024-15.88%
Report Date
Aug 7, 2024
EPS Beat/Miss
-3321.4%
Price Before
$30.79
Price After
$25.90
Avg Beat Reaction+2.36%
Avg Miss Reaction-9.09%
Beat Rate5 / 8 quarters
Largest Move+26.96% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BNGO ends December
Bionano Genomics, Inc. (BNGO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.76 — beating the analyst consensus of $-0.81 by +6.2%. BNGO has beaten EPS estimates for 5 consecutive quarters. The next BNGO earnings date is expected around September 1, 2026.
Each quarter, investors track BNGO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BNGO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BNGO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BNGO earnings · 5 questionsBionano Genomics, Inc.'s next earnings report is expected around September 1, 2026. BNGO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BNGO historically reports after market close (AMC).
BNGO earnings datewhen is BNGO earningsBNGO next earnings datewhen does BNGO report earningsBNGO earnings calendar
▸ Source: FMP · Bionano Genomics, Inc. SEC filings · US GAAP · Bionano Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026